AnorMED asks BC Supreme Court to order dissidents to correct information in proxy circular
07 April 2006 - 1:40AM
PR Newswire (US)
VANCOUVER, April 6 /PRNewswire-FirstCall/ -- AnorMED Inc. (TSX:
AOM; AMEX: AOM) announces that it has filed a Petition with the
Supreme Court of British Columbia, asking that a group of dissident
shareholders led by Baker Bros. Advisors LLC, be ordered to correct
a misstatement published in their proxy circular. Baker Bros. is
seeking to replace the AnorMED board of directors with its own
slate of directors. In its dissident circular, Baker Bros.
selectively quotes from a previously unpublished, confidential
report prepared for AnorMED by Blair Franklin Capital Partners Inc.
Blair Franklin was engaged to advise an independent committee of
AnorMED's board on financing options for the company. Based on
Blair Franklin's advice, on December 8, 2005, AnorMED closed a
successful $34.5 million bought deal financing. AnorMED believes
that Baker Bros.' circular mischaracterizes Blair Franklin's
recommendation. The court has ordered Baker Bros. to respond to
AnorMED's Petition by Saturday, April 8, 2006, and has ordered a
hearing for Monday, April 10, 2006. In order to give all
shareholders access to the same information, AnorMED has now posted
a copy of the Blair Franklin report on its website at
http://www.anormed.com/. AnorMED shareholders are recommended to
vote their BLUE AnorMED proxy in favour of the AnorMED Slate.
Proxies must be returned by April 19, 2006 at 10:00 a.m. Vancouver
time for your vote to count. The AnorMED Management Proxy Circular,
which has been mailed to shareholders and filed with regulators, is
available on the Company website (http://www.anormed.com/) and
SEDAR at http://www.sedar.com/. For more information call North
American toll free number 1-866-267-8910, or collect at
416-642-7069. If shareholders previously returned a Yellow
Dissident Proxy, they have every legal right to change their vote,
by simply signing, dating and returning a Blue proxy. AnorMED is a
chemistry-based biopharmaceutical company focused on the discovery,
development and commercialization of new therapeutic products in
the areas of hematology, HIV and oncology. The Company has a
product in Phase III development, a product in Phase II development
and a research program focused on a novel class of compounds that
target specific chemokine receptors known to be involved in a
variety of diseases including HIV. Additional information on
AnorMED Inc. is available on the Company's website
http://www.anormed.com/. Note: Certain of the statements contained
in this press release may contain forward-looking statements and
forward-looking information within the meaning of applicable
securities laws, including the Ontario Securities Act, Section 27A
of the U.S. Securities Act of 1933 and Section 21E of the U.S.
Securities Exchange Act of 1934. Statements or information
regarding strategy, future operations, future financial position,
future revenues, projected costs, prospects and plans and
objectives of management are forward-looking statements. The words
"anticipates, "believes", "budgets", "could", "estimates",
"expects," "forecasts", "intends", "may", "plans", "projects",
"schedule", "should", "will", "would" and similar expressions are
intended to identify forward-looking statements or information,
although not all forward-looking statements or information contain
these identifying words. Plans, intentions or expectations
disclosed in any forward-looking statements or information should
not be read as guarantees of future results or events, and will not
necessarily be accurate indications of whether or the times at or
by which such results or events will be achieved. Forward-looking
statements or information involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the Company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward- looking
statements or information. Investors are referred to the discussion
of such risks, uncertainties and other factors in AnorMED's Final
Short Form Prospectus dated December 1, 2005 filed on SEDAR with
Canadian securities regulatory authorities and in Exhibit 99.1 to
AnorMED's Report on Form 6-K filed with the U.S. Securities and
Exchange Commission on December 23, 2005. Except as required by
law, AnorMED expressly disclaims any intention and undertakes no
obligation to update any forward-looking statements or information
as conditions change. For further information: Elisabeth Whiting,
M.Sc. Dr. Michael Abrams VP Corporate Development & President
& CEO Communications Tel: 604-530-1057 Tel: 604-532-4667
E-mail: Cell: 604-763-4682 E-mail: DATASOURCE: AnorMED Inc.
CONTACT: Dr. Michael Abrams, President & CEO, Tel: (604)
530-1057, E-mail: ; Elisabeth Whiting, M.Sc., VP Corporate
Development & Communications, Tel: (604) 532-4667, Cell: (604)
763-4682, E-mail:
Copyright